Mar 15, 2023 8:35am EDT Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro
Mar 08, 2023 8:30am EST Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
Feb 15, 2023 4:05pm EST Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
Jan 27, 2023 4:05pm EST Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules
Jan 25, 2023 1:00pm EST Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules
Jan 25, 2023 8:35am EST Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
Jan 25, 2023 8:05am EST Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
Dec 12, 2022 4:05pm EST Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
Dec 07, 2022 4:05pm EST Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs